Preoperative celecoxib use does not increase risk of myocardial infarction and may be protective against thromboembolic complications following total joint arthroplasty

The purpose of this study was to determine if preoperative celecoxib treatment raises the risk of postoperative 1) myocardial infarctions, 2) thromboembolic complications, 3) acute kidney injuries, 4) transfusions, and 5) readmissions. Using the administrative claims database, PearlDiver, a retrospective study from January 2010 to October 2020 was conducted. Patients undergoing total knee or hip arthroplasty for osteoarthritis with recent celecoxib prescription were included, excluding those with MI history. Propensity score matched 230,587 patients (TKA: 38,433 celecoxib, 192,154 control; THA: 21,603 celecoxib, 108,008 control). Outcomes evaluated: 90-day myocardial infarction, DVT, PE, VTE, AKIs, transfusion, readmission. Multivariate logistic regression calculated odds ratios, 95 % CIs, p-values. Welch's t-tests assessed differences in stay lengths, costs (p